Opportunities for Manufacturers in UMIC: How Price Reduction Can Drive Adoption Source: UMIC countries as per World Bank definition In price-sensitive markets, affordability not awareness is the dominant adoption gate for GLP-1 obesity therapies
In contrast, price-driven adoption in lower-middle-income countries remains capped near 15% unless public reimbursement expands
Dulaglutide (Brand name: Trulicity) Administered as a weekly injection, primarily for diabetes
These next-generation microbes are selected to support microbiome diversity, gut barrier health, and metabolic wellness in a convenient daily-use formula
Obesity and excess fat can have serious health effects across the lifespan, but particularly as people age
These can include powerful appetite suppressants like phentermine as well as injection treatments like HCG (human chorionic gonadotropin) and GLP-1 therapies like Ozempic and Wegovy